Limits...
A case of combined hepatocellular-cholangiocarcinoma with favorable response to systemic chemotherapy.

Kim GM, Jeung HC, Kim D, Kim JH, Yoon SH, Jung ES, Shin SJ - Cancer Res Treat (2010)

Bottom Line: Because of its low incidence, the information on clinical outcomes of cHCC-CC is very limited and there are no published reports describing non-surgical treatment options for cHCC-CC.After completing 8 cycles of 2nd line therapy, we changed the regimen to a fluorouracil (5-FU) mono therapy because of the toxicities associated with doxorubicin and cisplatin.To date, the patient has completed his 15th cycle of 5-FU mono therapy with the disease status remaining stable during 18 months of follow-up.

View Article: PubMed Central - PubMed

Affiliation: Division of Oncology, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea.

ABSTRACT
Combined hepatocellular-cholangiocarcinoma (cHCC-CC) is a rare form of primary liver cancer composed of cells with histopathologic features of both hepatocellular carcinoma (HCC) and cholangiocarcinoma (CC). Because of its low incidence, the information on clinical outcomes of cHCC-CC is very limited and there are no published reports describing non-surgical treatment options for cHCC-CC. We report a case of cHCC-CC exhibiting a favorable response to systemic chemotherapy with doxorubicin and cisplatin. A 62-year-old man who recurred after a right lobectomy for cHCC-CC received sorafenib for palliative systemic therapy, but follow up imaging studies showed disease progression. He received 2nd line chemotherapy with doxorubicin at 60 mg/m(2) together with cisplatin at 70 mg/m(2). After 2 cycles of chemotherapy, a computed tomography scan of the chest showed markedly decreased size and number of the multiple lung metastases. After completing 8 cycles of 2nd line therapy, we changed the regimen to a fluorouracil (5-FU) mono therapy because of the toxicities associated with doxorubicin and cisplatin. To date, the patient has completed his 15th cycle of 5-FU mono therapy with the disease status remaining stable during 18 months of follow-up.

No MeSH data available.


Related in: MedlinePlus

The follow up imaging studies at disease progression after 2 cycles of sorafenib. (A) Whole body bone scan showed multiple uptakes in T-spine, left scapula, ribs. (B) Chest radiograph showed bilateral multiple various sized lung nodules. (C) CT scan of chest showed innumerable hematogenous lung metastasis.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC3021743&req=5

Figure 2: The follow up imaging studies at disease progression after 2 cycles of sorafenib. (A) Whole body bone scan showed multiple uptakes in T-spine, left scapula, ribs. (B) Chest radiograph showed bilateral multiple various sized lung nodules. (C) CT scan of chest showed innumerable hematogenous lung metastasis.

Mentions: A 62-year old man was admitted to our hospital for recurrence of cHCC-CC. He was diagnosed as stage II HCC (T2N0M0) by tumor marker and imaging study in February 2004. The patient did not have any known risk factors for HCC and thus underwent a right lobectomy at that time. Surgical pathologic report revealed cHCC-CC (Fig. 1). Four years after the operation, a computed tomography (CT) scan of the chest showed multiple lung metastasis, along with a whole body bone scan (WBBS) revealing multiple bone metastasis (T-spine, rib, scapula). At the time of recurrence, laboratory tests including a liver function test were normal and his overall performance status was categorized as good. He received 1st line palliative therapy with sorafenib from July 2008 to September 2008, but a follow up imaging study showed disease progression with further lung metastasis (Fig. 2) and a PIVKA-II elevated to more than 2,000 mAU/mL.


A case of combined hepatocellular-cholangiocarcinoma with favorable response to systemic chemotherapy.

Kim GM, Jeung HC, Kim D, Kim JH, Yoon SH, Jung ES, Shin SJ - Cancer Res Treat (2010)

The follow up imaging studies at disease progression after 2 cycles of sorafenib. (A) Whole body bone scan showed multiple uptakes in T-spine, left scapula, ribs. (B) Chest radiograph showed bilateral multiple various sized lung nodules. (C) CT scan of chest showed innumerable hematogenous lung metastasis.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC3021743&req=5

Figure 2: The follow up imaging studies at disease progression after 2 cycles of sorafenib. (A) Whole body bone scan showed multiple uptakes in T-spine, left scapula, ribs. (B) Chest radiograph showed bilateral multiple various sized lung nodules. (C) CT scan of chest showed innumerable hematogenous lung metastasis.
Mentions: A 62-year old man was admitted to our hospital for recurrence of cHCC-CC. He was diagnosed as stage II HCC (T2N0M0) by tumor marker and imaging study in February 2004. The patient did not have any known risk factors for HCC and thus underwent a right lobectomy at that time. Surgical pathologic report revealed cHCC-CC (Fig. 1). Four years after the operation, a computed tomography (CT) scan of the chest showed multiple lung metastasis, along with a whole body bone scan (WBBS) revealing multiple bone metastasis (T-spine, rib, scapula). At the time of recurrence, laboratory tests including a liver function test were normal and his overall performance status was categorized as good. He received 1st line palliative therapy with sorafenib from July 2008 to September 2008, but a follow up imaging study showed disease progression with further lung metastasis (Fig. 2) and a PIVKA-II elevated to more than 2,000 mAU/mL.

Bottom Line: Because of its low incidence, the information on clinical outcomes of cHCC-CC is very limited and there are no published reports describing non-surgical treatment options for cHCC-CC.After completing 8 cycles of 2nd line therapy, we changed the regimen to a fluorouracil (5-FU) mono therapy because of the toxicities associated with doxorubicin and cisplatin.To date, the patient has completed his 15th cycle of 5-FU mono therapy with the disease status remaining stable during 18 months of follow-up.

View Article: PubMed Central - PubMed

Affiliation: Division of Oncology, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea.

ABSTRACT
Combined hepatocellular-cholangiocarcinoma (cHCC-CC) is a rare form of primary liver cancer composed of cells with histopathologic features of both hepatocellular carcinoma (HCC) and cholangiocarcinoma (CC). Because of its low incidence, the information on clinical outcomes of cHCC-CC is very limited and there are no published reports describing non-surgical treatment options for cHCC-CC. We report a case of cHCC-CC exhibiting a favorable response to systemic chemotherapy with doxorubicin and cisplatin. A 62-year-old man who recurred after a right lobectomy for cHCC-CC received sorafenib for palliative systemic therapy, but follow up imaging studies showed disease progression. He received 2nd line chemotherapy with doxorubicin at 60 mg/m(2) together with cisplatin at 70 mg/m(2). After 2 cycles of chemotherapy, a computed tomography scan of the chest showed markedly decreased size and number of the multiple lung metastases. After completing 8 cycles of 2nd line therapy, we changed the regimen to a fluorouracil (5-FU) mono therapy because of the toxicities associated with doxorubicin and cisplatin. To date, the patient has completed his 15th cycle of 5-FU mono therapy with the disease status remaining stable during 18 months of follow-up.

No MeSH data available.


Related in: MedlinePlus